Trial reportJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025
Dosimetry of [
Trial report in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Fraction-dependent dose dynamics and clinical safety in high-risk neuroblastoma treated with [European journal of nuclear medicine and molecular imaging · 2026Trial
- Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.Frontiers in endocrinology · 2025Trial
- Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Review
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- FAP-Targeted Radionuclide Therapy: Mechanisms, Clinical Applications, and Combination Strategies.Biomedicines · 2026Review
- Personalised Dosimetry in Nuclear Medicine: Bridging Physics, Biology and AI for Next Generation Radiopharmaceutical Therapy.Nuclear medicine and molecular imaging · 2026Review
- Peptide receptor radionuclide therapy in neuroendocrine tumours: advances, combination strategies, and future directions.European journal of nuclear medicine and molecular imaging · 2026Review
- Rare-Earth Elements at the Interface of Chemistry and Cancer Therapy.Molecules (Basel, Switzerland) · 2026Review
- Inter-institutional variability in kidney dosimetry duringRadiological physics and technology · 2026Article
- Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.EJNMMI research · 2026Article
- Paving the Way for CCK2R-Targeted Peptide Receptor Radionuclide Therapy with [Pharmaceutics · 2026Article
- Rational Radionuclide Therapy for Recurrent Meningioma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Beyond treatment eligibility: rethinking theranostic targets.Frontiers in oncology · 2026Article
- Review
- The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025Review
- Review
- Assessment of Early Cardiotoxicity and Cardiac Dysfunction of Radioligand Therapy in Patients with Neuroendocrine Tumors.Cancers · 2025Article
- Fibroblast Activation Protein-Targeted Theranostics: Current Status in Clinical Development.Nuclear medicine and molecular imaging · 2025Review
- Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.bioRxiv : the preprint server for biology · 2025Article
- Insight from the ESMO Targeted Anticancer Therapies Congress 2025.Nature cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
This substudy of the phase III NETTER-1 trial evaluated [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.